Milestone Scientific Inc. Common Stock (MLSS)

FairStock Score: 36/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach Milestone Scientific as a Graham-style asset buyer: what is the business worth, and what protects it? The company sells injection technology for dental and medical use, with a tiny 15-person operation. Revenue is small: fiscal Q2 2026, the quarter ended 2026-06-30, had $2.8M of revenue and a net loss of $1.1M; fiscal Q1 2026 had $2.2M of revenue and a net loss of $839,853. For the full fiscal year 2025, revenue was $9.0M and net loss was $5.7M. In fiscal 2024 and 2023, the company also lost money, $4.7M and $6.9M respectively. That record fits FairStock's Lynch category of none, because it lost money in each of the last four years. The balance sheet does show a low debt-to-equity ratio of 0.18, and the latest quarter's loss narrowed from fiscal Q2 2025's $1.5M loss on $2.3M of revenue. But trailing free cash flow is -$657,758, and FairStock's FCF yield is -2.2%. FairStock also calculates a negative ROE of -121.67%, ROCE of -31.28%, a Piotroski F-Score of 4/9, and an Altman Z-Score of -18.59, which point to financial fragility. At the 2026-10-13 close of $0.34, FairStock shows P/E of -6.80 and P/B of 8.50. A moat? I see no clear durable advantage in these numbers. The price may look low in absolute terms, but without profits, positive cash flow, or a demonstrated growth engine, it is not a classic Graham bargain. I would want evidence of durable revenue growth and self-funding before calling this a sound value.

In plain English: Milestone Scientific makes injection devices for dental and medical use, including the Wand dental handpiece. The business looks weak: it has not made a profit and has lost money in each of the last four years. At $0.34 a share on 2026-10-13, the price looks risky and not clearly cheap compared with its current sales and losses.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer